Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Gs 6201. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B known ✓ | P29275 | 20/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 18/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 17/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 12/20 | 1.00 |
| ▸ | PLK4 | O00444 | 1/20 | 1.00 |
| ▸ | CDK2 | P24941 | 1/20 | 1.00 |
| ▸ | IRAK1 | P51617 | 1/20 | 1.00 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 1.00 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 1.00 |
| ▸ | CSNK1G3 | Q9Y6M4 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gs 6201 SCHEMBL29504137 | 1.00 | ADORA2B (1.00) | ADORA2BADORA2AADORA1ADORA3PLK4 | |
| Gs 6201 SCHEMBL29504138 | 1.00 | ADORA2B (1.00) | ADORA2BADORA2AADORA1ADORA3PLK4 | |
| Gs 6201 SCHEMBL29504135 | 1.00 | ADORA2B (1.00) | ADORA2BADORA2AADORA1ADORA3PLK4 | |
| Gs 6201 SCHEMBL29504136 | 1.00 | ADORA2B (1.00) | ADORA2BADORA2AADORA1ADORA3PLK4 | |
| SCHEMBL242517 | 0.97 | ADORA2B (1.00) | ADORA2BADORA2AADORA1ADORA3PLK4 | |
| SCHEMBL1944742 | 0.95 | ADORA2B (1.00) | ADORA2BADORA2AADORA1ADORA3PLK4 | |
| SCHEMBL243037 | 0.93 | ADORA2B (1.00) | ADORA2BADORA2AADORA1ADORA3PLK4 | |
| SCHEMBL243736 | 0.90 | ADORA2B (0.86) | ADORA2BADORA2AADORA1ADORA3PLK4 | |
| SCHEMBL1944731 | 0.90 | ADORA2B (1.00) | ADORA2BADORA2AADORA1ADORA3PLK4 | |
| SCHEMBL2685809 | 0.90 | ADORA2B (0.85) | ADORA2BADORA2AADORA1ADORA3PLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 343 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| US-20240219394-A1 | METHOD FOR MEASURING RESPONSE OF OLFACTORY RECEPTOR TO SUBSTANCE | AJINOMOTO CO., INC. (JP) | 2024-07-04 | — | — | US | claimed |
| EP-4382612-A1 | METHOD FOR MEASURING RESPONSE OF OLFACTORY RECEPTOR TO SUBSTANCE | AJINOMOTO CO., INC. (JP) | 2024-06-12 | — | — | EP | claimed |
| US-20230365564-A1 | COCRYSTALS OF AN ADENOSINE A2B RECEPTOR ANTAGONIST | TEON THERAPEUTICS INC (US) | 2023-11-16 | — | — | US | claimed |
| EP-4211135-A1 | COCRYSTALS OF AN ADENOSINE A2B RECEPTOR ANTAGONIST | Teon Therapeutics, Inc. (US) | 2023-07-19 | — | — | EP | claimed |
| CN-116322698-A | Co-crystals of adenosine A2B receptor antagonists | 泰昂治疗公司 | 2023-06-23 | — | — | CN | claimed |
| WO-2023013791-A1 | METHOD FOR MEASURING RESPONSE OF OLFACTORY RECEPTOR TO SUBSTANCE | 味の素株式会社 | 2023-02-09 | — | — | WO | claimed |
| US-20220257603-A1 | COMBINATION THERAPY FOR TREATING MTAP-DEFICIENT TUMORS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-08-18 | — | — | US | claimed |
| US-20140243358-A1 | METHOD OF PREVENTING AND TREATING HEPATIC DISEASE USING A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD SCIENCES, INC. (US) | 2014-08-28 | — | — | US | claimed |
| EP-2694074-A1 | USE OF A2B ADENOSINE RECEPTOR ANTAGONISTS FOR TREATING HEART FAILURE AND ARRHYTHMIA IN POST-MYOCARDIAL INFARCTION PATIENTS | Gilead Sciences, Inc. (US) | 2014-02-12 | — | — | EP | claimed |
| US-20080153856-A1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. | 2008-06-26 | — | — | US | claimed |
| US-20080085908-A1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. | 2008-04-10 | — | — | US | claimed |
| US-20070219221-A1 | administration of therapeutically effective amount of 3-ethyl-1-propyl-8-(1-{[3-(trifluoromethyl)phenyl]methyl}pyrazol-4-yl)-1,3,7-trihydropurine-2,6-dione, wherein hepatic disease is selected from necrosis, fibrosis, cholestasis, cirrhosis, viral and alcoholic hepatitis, ingestion of hepatotoxic drugs | GILEAD SCIENCES, INC. | 2007-09-20 | — | — | US | claimed |
| EP-1789053-A2 | METHOD OF WOUND HEALING USING A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2007-05-30 | — | — | EP | claimed |
| US-7125993-B2 | A2B adenosine receptor antagonists | CV THERAPEUTICS, INC. (US) | 2006-10-24 | — | — | US | claimed |
| US-20060159627-A1 | Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. | 2006-07-20 | — | — | US | claimed |
| WO-2006028810-A2 | METHOD OF WOUND HEALING USING A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2006-03-16 | — | — | WO | claimed |
| US-20060058322-A1 | Method of wound healing using A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. | 2006-03-16 | — | — | US | claimed |
| US-6825349-B2 | PURINE DERIVATIVES FOR TREATMENT OF GASTROINTESTINAL DISORDERS, IMMUNOLOGICAL DISORDERS, NEUROLOGICAL DISORDERS | CV THERAPEUTICS INC. | 2004-11-30 | — | — | US | claimed |
| US-20040176399-A1 | A2B adenosine receptor antagonists | GILEAD PALO ALTO, INC. | 2004-09-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243358-A1 | METHOD OF PREVENTING AND TREATING HEPATIC DISEASE USING A2B ADENOSINE RECEPTOR ANTAGONISTS | ADORA2B, ADORA2A, ADORA1 | ADORA2B 1/4885ADORA2A 2/4885ADORA1 3/4885 |
| US-20070219221-A1 | administration of therapeutically effective amount of 3-ethyl-1-propyl-8-(1-{[3-(trifluoromethyl)phenyl]methyl}pyrazol-4-yl)-1,3,7-trihydropurine-2,6-dione, wherein hepatic disease is selected from necrosis, fibrosis, cholestasis, cirrhosis, viral and alcoholic hepatitis, ingestion of hepatotoxic drugs | ADORA2B, ADORA2A, ADORA1 | ADORA2B 1/4885ADORA2A 2/4885ADORA1 3/4885 |
| US-20080085908-A1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | ADORA2B, ADORA2A, ADORA1 | ADORA2B 1/4885ADORA2A 2/4885ADORA1 3/4885 |
| US-20040176399-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | ADORA2B 1/4885ADORA2A 2/4885ADORA1 3/4885 |
| US-20080153856-A1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | ADORA2B, ADORA2A, ADORA1 | ADORA2B 1/4885ADORA2A 2/4885ADORA1 3/4885 |
| US-20230365564-A1 | COCRYSTALS OF AN ADENOSINE A2B RECEPTOR ANTAGONIST | ADORA2A, ADORA2B, ADORA3 | ADORA2B 2/4885ADORA2A 1/4885ADORA1 4/4885 |
| US-20060058322-A1 | Method of wound healing using A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | ADORA2B 1/4885ADORA2A 2/4885ADORA1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.